Dendritic Cell Dysfunction in Post-CLP Immunosuppression
CLP 免疫抑制后树突状细胞功能障碍
基本信息
- 批准号:7104338
- 负责人:
- 金额:$ 12.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-08-01 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:Pseudomonasantigen presentationbactericidal immunitycellular immunitycellular pathologydendritic cellsdisease /disorder proneness /riskenzyme linked immunosorbent assayflow cytometrygastrointestinal infectionhematopoietic growth factorileocolonic regionimmunosuppressioninjury /disease stressorinterferon gammainterleukin 12intestine surgerylaboratory mouseleukocyte activation /transformationmacrophagesecondary infectionsuppressor T lymphocytetissue /cell culture
项目摘要
DESCRIPTION (provided by applicant):
This K08 application is a proposal for the development of the applicant towards scientific independence while performing research to develop novel insights into the pathophysiology of injury-induced immunosuppression and study a novel therapeutic strategy for this syndrome. The applicant will investigate post-injury immunosuppression under the guidance of an advisory committee led by Drs. Edward Sherwood and Frank Schmalstieg. These investigators have each made strong contributions to the fields of sepsis and burn injury, and have committed to providing the applicant with strong mentorship and training in molecular and immunologic experimental techniques. The applicant will also benefit from his unique placement within the Shriners' Burns Institute which provides avenues for collaboration and development of junior investigators through weekly scientific review meetings. Finally, the applicant intends to round out his development with participation in a number of didactic pursuits, including immunology journal clubs and weekly seminars, and post-graduate classes in immunology, flow cytometry, molecular biology. While investigating the innate immune response during an immunosuppressed state, the applicant will acquire new knowledge and skills necessary to develop a strong background in basic and applied immunology. The Dept. of Anesthesiology and the Shriners' Burns Institute at UTMB provide expertise from diverse resources and provide an ideal setting for training scientists. Patient survival after a severe injury or infectious insult has been greatly improved by the capacity of physicians to provide fluid resuscitation and physiological support. However, secondary infection is a major cause of morbidity and mortality in these patients. Post-injury immunosuppression is emerging as a predisposing factor for the development of secondary infection. Our preliminary studies show that dendritic cell and macrophage dysfunction contribute significantly to the state of immunosuppression observed in the critically ill host. The purpose of the proposed research is to further define dendritic cell and macrophage function during the post-injury period and examine the ability of the hemopoietic factor Flt3-L to improve dendritic cell function and resistance to secondary infection. The specific aims include: 1) Investigating the role that altered dendritic cell function plays in diminished bacterial clearance after cecal ligation and puncture; 2) Determining if Flt3-L expansion of dendritic cells results in increased IL-12 and IFNgamma expression and enhanced resistance to infection; and 3) Investigating the role that altered macrophage function plays in diminished bacterial clearance after cecal ligation and puncture with particular emphasis on the study of a subset of macrophages that have been termed 'natural suppressor' cells and have the potential to differentiate into dendritic cells.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERLE D MURPHEY其他文献
ERLE D MURPHEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERLE D MURPHEY', 18)}}的其他基金
Dendritic Cell Dysfunction in Post-CLP Immunosuppression
CLP 免疫抑制后树突状细胞功能障碍
- 批准号:
6968546 - 财政年份:2005
- 资助金额:
$ 12.05万 - 项目类别:
Dendritic Cell Dysfunction in Post-CLP Immunosuppression
CLP 免疫抑制后树突状细胞功能障碍
- 批准号:
7664265 - 财政年份:2005
- 资助金额:
$ 12.05万 - 项目类别:
Dendritic Cell Dysfunction in Post-CLP Immunosuppression
CLP 免疫抑制后树突状细胞功能障碍
- 批准号:
7903113 - 财政年份:2005
- 资助金额:
$ 12.05万 - 项目类别:
Dendritic Cell Dysfunction in Post-CLP Immunosuppression
CLP 免疫抑制后树突状细胞功能障碍
- 批准号:
7475691 - 财政年份:2005
- 资助金额:
$ 12.05万 - 项目类别:
Dendritic Cell Dysfunction in Post-CLP Immunosuppression
CLP 免疫抑制后树突状细胞功能障碍
- 批准号:
7270555 - 财政年份:2005
- 资助金额:
$ 12.05万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 12.05万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 12.05万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 12.05万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 12.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 12.05万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 12.05万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 12.05万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 12.05万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 12.05万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 12.05万 - 项目类别:














{{item.name}}会员




